Posts

Posted on

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

NEW YORK–(BUSINESS WIRE)–
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that new nonclinical data for taletrectinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) will be presented at the American Association for Cancer Research (AACR) Annual Meeting taking place April 25–30, 2025 in Chicago, Illinois.

Presentation Overview:

Title: Taletrectinib, a next generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenografts

Presenter: Hitisha Patel, Ph.D., Director of Research, Nuvation Bio

Session Category: Experimental and Molecular Therapeutics

Session Title: Kinase and Phosphatase Inhibitors 3

Date: Tuesday,April29, 2025

Session Time and Location: 2:00 – 5:00 p.m. CT / 3:00 – 6:00 p.m. ET; Poster Section 20

Poster Board Number: 22

Abstract Number: 5612

The materials will be made available in the Publications section of Nuvation Bio’s website after the presentation.

About Taletrectinib

Taletrectinib is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor specifically designed for the treatment of patients with advanced ROS1+ NSCLC. Taletrectinib is being evaluated for the treatment of patients with advanced ROS1+ NSCLC in two Phase 2 single-arm pivotal studies: TRUST-I (NCT04395677) in China, and TRUST-II (NCT04919811), a global study.

Based on pooled results of the TRUST-I and TRUST-II clinical studies, the U.S. FDA has accepted and granted Priority Review to Nuvation Bio’s NDA for taletrectinib for advanced ROS1+ NSCLC (line agnostic, full approval) and assigned a PDUFA goal date of June 23, 2025. The U.S. FDA previously granted taletrectinib Breakthrough Therapy Designation for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC who either have or have not previously been treated with ROS1 TKIs, and Orphan Drug Designation for the treatment of patients with ROS1+ NSCLC and other NSCLC indications. In January 2025, China’s NMPA approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC.

About Nuvation Bio

Nuvation Bio is a global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s programs include taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit www.nuvationbio.com or follow the Company on LinkedIn and X (@nuvationbioinc).

Nuvation Bio Investor Contact:

[email protected]

Nuvation Bio Media Contact:

[email protected]

KEYWORDS: United States North America Illinois New York

INDUSTRY KEYWORDS: Science Other Science Biotechnology Research Pharmaceutical Oncology Health Other Health

MEDIA:

Logo
Logo
Posted on

Benson Hill Receives Court Approval of First-Day Motions to Support Ongoing Operations During Chapter 11 Process

Benson Hill Receives Court Approval of First-Day Motions to Support Ongoing Operations During Chapter 11 Process

  • Operations will continue as normal for the Company during the transitional period.
  • Employee wages and benefits will be paid following DIP financing approval.
  • Court authorizes vendor payments and critical operational support.

ST. LOUIS–(BUSINESS WIRE)–Benson Hill, Inc. (Nasdaq: BHIL, “Benson Hill”), a seed innovation company, today announced that the U.S. Bankruptcy Court for the District of Delaware has approved the Company’s initial “first-day” motions following its voluntary filing for relief under Chapter 11 of the U.S. Bankruptcy Code on March 20, 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325440772/en/

Benson Hill, Inc. (Nasdaq: BHIL, “Benson Hill”), a seed innovation company, today announced that the U.S. Bankruptcy Court for the District of Delaware has approved the Company’s initial “first-day” motions following its voluntary filing for relief under Chapter 11 of the U.S. Bankruptcy Code on March 20, 2025.

Benson Hill, Inc. (Nasdaq: BHIL, “Benson Hill”), a seed innovation company, today announced that the U.S. Bankruptcy Court for the District of Delaware has approved the Company’s initial “first-day” motions following its voluntary filing for relief under Chapter 11 of the U.S. Bankruptcy Code on March 20, 2025.

These approvals are expected to ensure business continuity as Benson Hill works to strengthen its financial position and continue advancing its work to deliver better feed, food, and fuel through innovative soybean seed genetics and soy quality traits.

The Court’s orders allow the Company and its affiliated debtors to continue day-to-day operations with minimal disruption, including:

  • Access to up to $11 million in debtor-in-possession (DIP) financing from existing lenders, including Expedition Ag Holdings, S2G Investments, Steve Kahn, and ProAgInvest, with an initial $3 million available immediately. These funds will support payroll, vendor payments, and other critical operating expenses.
  • Authorization to pay employee wages and benefits without interruption.
  • Ability to honor prepetition obligations to key business partners—including critical vendors, shippers, warehouse providers, and suppliers with administrative expense claims under section 503(b)(9)—to maintain operational continuity and preserve value in the business.
  • Permission to maintain existing cash management systems, bank accounts, and routine business operations.
  • Legal authorization for DIP lenders to credit bid for assets, along with other customary protections in the event of default.

“These approvals give us the opportunity to maintain momentum while we take the necessary steps to restructure our financial foundation,” said Dan Cosgrove, Interim Chief Executive Officer of Benson Hill. “We remain focused on delivering value to our customers and partners while positioning the business for long-term success and maximizing value for all of our stakeholders.”

A final hearing to consider approval of the full DIP financing and vendor-related motions is scheduled for April 16.

Additional information about the Chapter 11 process is available on the website maintained by the Company’s claims agent Stretto, Inc., at https://cases.stretto.com/bensonhill.

About Benson Hill

Benson Hill is a seed innovation company that unlocks nature’s genetic diversity in soy quality traits through a combination of its proprietary genetics, its AI-driven CropOS® technology platform, and its Crop Accelerator. Benson Hill collaborates with strategic partners to create value throughout the agribusiness supply chain to meet the demand for better feed, food, and fuel. For more information, visit bensonhill.com or X, formerly known as Twitter at @bensonhillinc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Among those risks, uncertainties and other factors are: (i) the Company’s ability to obtain Court approval with respect to motions or other requests made to the Court in the Chapter 11 process, including maintaining strategic control as a debtor-in-possession; (ii) the ability of the Company to negotiate and consummate a sale transaction; (iii) the effects of the Chapter 11 filing on the Company and on the interests of various constituents, including holders of the Company’s common stock; (iv) Court rulings in the Chapter 11 process in general; (v) the length of time that the Company will operate under Chapter 11 protection and the continued availability of operating capital during the pendency of the proceedings; (vi) risks associated with third party motions in the Chapter 11 process, which may interfere with the Company’s ability to negotiate and consummate a sale transaction; (vii) the potential adverse effects of the Chapter 11 proceedings on the Company’s liquidity or results of operations; (viii) increased advisory costs during the pendency of the proceedings; (ix) the impact of Nasdaq’s delisting of the Company’s common stock on the price and trading market of the Company’s common stock; and (x) other factors disclosed by the Company from time to time in its filings with the Securities and Exchange Commission, including those set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and its Quarterly Reports, which are available on the SEC’s website at www.sec.gov. There may be additional risks about which the Company is presently unaware or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any duty to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by law.

Christi Dixon: (636) 359-0797 / [email protected]

KEYWORDS: United States North America Missouri

INDUSTRY KEYWORDS: Apps/Applications Technology Other Retail Specialty Food/Beverage Data Management Agriculture Retail Natural Resources Artificial Intelligence

MEDIA:

Photo
Photo
Benson Hill, Inc. (Nasdaq: BHIL, “Benson Hill”), a seed innovation company, today announced that the U.S. Bankruptcy Court for the District of Delaware has approved the Company’s initial “first-day” motions following its voluntary filing for relief under Chapter 11 of the U.S. Bankruptcy Code on March 20, 2025.
Logo
Logo
Posted on

CPKC announces filing of proxy circular

PR Newswire


CALGARY, AB
, March 25, 2025 /PRNewswire/ – Canadian Pacific Kansas City (TSX: CP) (NYSE: CP) (CPKC) announced today that it has filed its notice of meeting and management proxy circular for CPKC’s 2025 annual and special meeting of shareholders with Canadian and U.S. securities regulators. A copy of the proxy material is available at investor.cpkcr.com.

The annual meeting of shareholders will be held virtually on April 30, 2025 at 9 a.m. MT.

Although shareholders will not be able to attend the meeting in person, a virtual-only format allows for greater participation of shareholders, including voting on business properly brought before the meeting and submitting questions for consideration. Shareholders can vote by proxy in advance of the meeting as in prior years and online during the meeting.

Detailed instructions for shareholders to participate in the meeting and a copy of the Virtual AGM User Guide are available at investor.cpkcr.com. CPKC will also send this information directly to shareholders.

About CPKC
With its global headquarters in Calgary, Alta., Canada, CPKC is the first and only single-line transnational railway linking Canada, the United States and México, with unrivaled access to major ports from Vancouver to Atlantic Canada to the Gulf of México to Lázaro Cárdenas, México. Stretching approximately 20,000 route miles and employing 20,000 railroaders, CPKC provides North American customers unparalleled rail service and network reach to key markets across the continent. CPKC is growing with its customers, offering a suite of freight transportation services, logistics solutions and supply chain expertise. Visit cpkcr.com to learn more about the rail advantages of CPKC. CP-IR

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cpkc-announces-filing-of-proxy-circular-302411271.html

SOURCE CPKC

Posted on

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC)

Three additional posters highlighting the potential for broad therapeutic applications of azenosertib as both a single agent and combination therapy as shown in preclinical models

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced four poster presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, IL.

AACR poster presentation details are below:

Title: “Loss of RB1 sensitizes TP53-mutated cancer cells to WEE1 inhibition by azenosertib”
Session Title: Cell Cycle Effects of Anticancer Drugs
Location: Poster Section 17, Poster Board Number 16
Abstract Number: 372
Date/Time: Sunday, April 27, 2024, 2:00 p.m. – 5:00 p.m. CDT
Presenting Author: Gabriel Kim, PhD

Title: “Cell-free DNA molecular response predicts clinical efficacy in HGSOC patients treated with azenosertib”
Session Title: Liquid Biopsy: Circulating Nucleic Acids 1
Location: Poster Section 29, Poster Board Number 19
Abstract Number: 3254
Date/Time: Monday, April 28, 2024, 2:00 p.m. – 5:00 p.m. CDT
Presenting Author: Jinkil Jeong, PhD

Title: “Azenosertib is a potent and selective WEE1 kinase inhibitor with broad antitumor activity across a range of solid tumors”
Session Title: DNA Damage Response and Modulation of DNA Repair 2
Location: Poster Section 15, Poster Board Number 25
Abstract Number: 4208
Date/Time: Tuesday, April 29, 2024, 9:00 a.m. – 12:00 p.m. CDT
Presenting Author: Wen Liu, PhD

Title: “The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor activity with encorafenib + cetuximab in multiple BRAFV600E models”
Session Title: Targeted Therapies and Combinations 2
Location: Poster Section 34, Poster Board Number 28
Abstract Number: 4730
Date/Time: Tuesday, April 29, 2024, 9:00 a.m. – 12:00 p.m. CDT
Presenting Author: Harsh Shah, PhD

The posters can be accessed through the “Supporting Publications” tab on the “Our Approach” section of the Zentalis website at the time of each presentation’s starting session.

About Azenosertib

Azenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.

About Zentalis Pharmaceuticals

Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the potential for cell-free DNA molecular response as a surrogate endpoint to measure clinical efficacy of azenosertib in patients with HGSOC; the potential benefits of azenosertib, including the potential for broad therapeutic applications of azenosertib as single agent and combination therapy; the potential to advance research on additional areas of opportunity for azenosertib outside PROC; the potential for azenosertib to be first-in-class and best-in-class; and the broad franchise potential of azenosertib. The terms “opportunity” and “potential” and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our plans, including the costs thereof, of development of companion diagnostics; our substantial dependence on the success of our lead product candidate, azenosertib; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; failure to identify additional product candidates and develop or commercialize marketable products; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; and the other important factors discussed under the caption “Risk Factors” in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release. 

Contact: 
Haibo Wang – Chief Business Officer
Ron Moldaver – Investor Relations
[email protected]  



Posted on

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

  • First oral presentation of BOT/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors
  • New data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT/BAL Phase 1 trial to be presented

LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus’ neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster featuring new data from the advanced hepatocellular carcinoma (HCC) cohort of a Phase 1 study evaluating BOT/BAL in patients with advanced solid tumors. Data from two separate, independent studies of neoadjuvant treatment with BOT/BAL in colorectal cancer–UNICORN and NEST– were presented earlier this year at ASCO-GI.

Oral Presentation Details:

Presentation Title: Neoadjuvant botensilimab plus balstilimab in MMR proficient and deficient early-stage cancers: First results of the pan-cancer NEOASIS study (NCT06279130)

Presenting Author: Myriam Chalabi, MD, Netherlands Cancer Institute

Session Title: Aiming for Cure: Adjuvant and Neoadjuvant Approaches

Session Date and Time: 4/28/2025; 2:30:00 – 4:30:00 PM CT

Abstract Presentation Number: CT130

Poster Presentation Details:

Presentation Title: Results from a phase 1 study of botensilimab and balstilimab in treatment refractory hepatocellular carcinoma (NCT03860272)

Presenting Author: Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center

Session Title: Late-Breaking Research: Clinical Research 3

Session Date and Time: 4/29/2025; 2:00 – 5:00 PM CT

Location: Poster Section 53

Poster Board Number: 9

Abstract Presentation Number: LB365

About Botensilimab (BOT)

Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.

Approximately 1,100 patients have been treated with botensilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316.

About Balstilimab (BAL)

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in >900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investors

917-362-1370

[email protected]

Media

510-323-5188

[email protected]

KEYWORDS: United States North America Illinois Massachusetts

INDUSTRY KEYWORDS: Oncology Health Other Science Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo
Posted on

Perion Announces Filing of Annual Report on Form 20-F for Fiscal Year 2024

Perion Announces Filing of Annual Report on Form 20-F for Fiscal Year 2024

NEW YORK & TEL AVIV, Israel–(BUSINESS WIRE)–Perion Network Ltd. (NASDAQ and TASE: PERI), a leader in advanced technology solving for the complexities of modern advertising, announced today the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (SEC).

The annual report, containing audited consolidated financial statements for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 25, 2025, is now accessible on our website at https://www.perion.com/.

In addition to online availability, Shareholders may receive a hard copy of the report at no additional cost. To request a hard copy of the annual report, shareholders are welcome to contact Perion Network Ltd. through the details provided on our website or send an email to [email protected]

This press release is issued in compliance with Nasdaq Listing Rule 5250(d)(1)(C).

About Perion Network Ltd.

Perion is helping agencies, brands and retailers get better results with their marketing investments by providing advanced technology across digital channels. Through the Perion One platform, we are making digital advertising more effective by building solutions that continuously adapt to connect the dots between data, creative and channels.

For more information, visit Perion’s website at www.perion.com

Forward Looking Statements

This press release contains historical information and forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of Perion. The words “will,” “believe,” “expect,” “intend,” “plan,” “should,” “estimate” and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views, assumptions and expectations of Perion with respect to future events and are subject to risks and uncertainties. Many factors could cause the actual results, performance or achievements of Perion to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, or financial information, including, but not limited to, the current war between Israel and Hamas and any worsening of the situation in Israel (such as further mobilizations), the failure to realize the anticipated benefits of companies and businesses we acquired and may acquire in the future, risks entailed in integrating the companies and businesses we acquire, including employee retention and customer acceptance; the risk that such transactions will divert management and other resources from the ongoing operations of the business or otherwise disrupt the conduct of those businesses, potential litigation associated with such transactions, and general risks associated with the business of Perion including intense and frequent changes in the markets in which the businesses operate and in general economic and business conditions, loss of key customers, data breaches, cyber-attacks and other similar incidents, unpredictable sales cycles, competitive pressures, market acceptance of new products, changes in applicable laws and regulations as well as industry self-regulation, inability to meet efficiency and cost reduction objectives, changes in business strategy and various other factors, whether referenced or not referenced in this press release. Various other risks and uncertainties may affect Perion and its results of operations, as described in reports filed by Perion with the Securities and Exchange Commission from time to time, including its annual report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 25, 2025. Perion does not assume any obligation to update these forward-looking statements.

Perion Network Ltd.

Dudi Musler, VP of Investor Relations

+972 (54) 7876785

[email protected]

KEYWORDS: North America United States Middle East Israel Canada New York

INDUSTRY KEYWORDS: Software Digital Marketing Networks Marketing Advertising Data Management Communications Technology

MEDIA:

Logo
Logo
Posted on

Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

PR Newswire


INDIANAPOLIS
, March 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 – 30 in Chicago.

In an oral presentation, Lilly, in collaboration with Foghorn Therapeutics, will present new preclinical data for LY4050784, a selective inhibitor of SMARCA2, in combination with chemotherapy, pembrolizumab, and KRAS inhibitors in preclinical models of SMARCA4 mutant cancers. Preclinical data for LY4066434, a pan-KRAS inhibitor that is highly selective over HRAS and NRAS, will also be presented. Both programs are currently enrolling Phase 1 studies. 

Details on presentations are below:

Presentation Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors
Abstract Number: 3779
Session Date & Time:Monday, April 28, 2:30-4:30 p.m. CST
Session Title: Continuum of Innovation: Biological Therapeutic Agents
Presenter: Nathan Brooks

Presentation Title: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS
Abstract Number: 4375
Session Date & Time:Tuesday, April 29, 9 a.m.-12 p.m. CST
Session Title: RAS Inhibitors
Presenter: Hong Gao

For more information on Lilly’s Oncology pipeline click here.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly’s oncology pipeline, including therapies under development, and the timeline for future readouts, presentations, and other milestones relating to therapies under development and their clinical trials, and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, or that any of these therapies will receive initial regulatory approval or approvals for additional indications, as applicable, or be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.


Refer to:   

Megan Talon; [email protected]; 463-209-1470 (Media)

Michael Czapar; [email protected]; 317-617-0983 (Investors)

 

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-details-of-presentations-at-2025-american-association-for-cancer-research-aacr-annual-meeting-302409875.html

SOURCE Eli Lilly and Company

Posted on

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

WATERTOWN, Mass. and GOSSELIES, Belgium, March 25, 2025 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the poster presentations of preclinical data on EOS-215, a potential best-in-class antibody targeting TREM2, and a novel small molecule inhibiting PTPN1/2 at the American Association for Cancer Research (AACR) Annual Meeting, being held April 25-30, 2025 in Chicago, Illinois.

Poster Presentation Details

Abstract 3136, “EOS-215, a first-in-class TREM2 antagonist, designed to reprogram the tumor microenvironment and overcome resistance”

  • Session: Experimental and Molecular Therapeutics – Therapeutic Approaches to Attack the Tumor Microenvironment
  • Date and Time: Monday, April 28, 2025, 2:30 PM – 5:00 P.M. CDT
  • Location: Poster Section 24

Abstract 5609, “A novel PTPN1/2 inhibitor with high oral bioavailability enhances the antitumoral response”

  • Session: Experimental and Molecular Therapeutics – Kinase and Phosphatase Inhibitors 3
  • Date and Time: Tuesday, April 29, 2025, 2:30 PM – 5:00 P.M. CDT
  • Location: Poster Section 20

iTeos’ exhibit booth at the AACR Annual Meeting is booth #3240.

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

About EOS-215

EOS-215 is a potential best-in-class monoclonal antibody which blocks ligand binding to triggering receptor expressed on myeloid cells 2 (TREM2), switching off multiple tumor growth and survival promoting activities of tumor resident macrophages and effectively “reprogramming” the macrophages to allow for T cell activation. The therapeutic candidate has shown activity in both in vitro and in vivo highly immune resistant models and is currently in IND-enabling studies.

About PTPN1/2

iTeos has developed a novel small molecule inhibiting PTPN1/2. The PTPN1/2 phosphatases are negative regulators of cytokine signaling pathways and T cell receptor signaling. Inhibiting or depleting PTPN1/2 sensitizes cancer and immune cells to IFNγ, reshaping the tumor microenvironment and triggering a coordinated antitumor immune response.

Forward-Looking Statements

This press release contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential of EOS-215 to be best in class and the potential benefits of EOS-215 and iTeos’ novel PTPN1/2 inhibitor.

These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos’ control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: success in preclinical testing does not ensure that later clinical trials will be successful; the data for our product candidates may not be sufficient for obtaining regulatory approval to move into later stage trials or to commercialize products; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos’ control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, negative developments in the field of immuno-oncology, such as adverse events or disappointing results, including in connection with competitor therapies, and regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates; and those risks identified under the heading “Risk Factors” in iTeos’ Annual Report on Form 10-K for the period ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect iTeos’ business, results of operations and the trading price of iTeos’ common stock. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements other than as required by law.

For further information, please contact:

Investor Contact:

Carl Mauch
iTeos Therapeutics, Inc.
[email protected]

Media Contact:

[email protected]



Posted on

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting

– FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population

– Oral presentation on preclinical data for FHD-909 in combination with chemotherapy, pembrolizumab and KRAS inhibitors, in SMARCA4 mutant cancers

– Poster presentations on preclinical data for Selective CBP degrader in combination with chemotherapy and targeted agents and for Selective EP300 degrader in hematological malignancies

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new preclinical combination data for FHD-909, a potential first-in-class selective SMARCA2 inhibitor will be presented as an oral presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025, in Chicago, Illinois. Poster presentations on the Phase 1 trial design for FHD-909 and on preclinical data for the Selective CBP program and the Selective EP300 degrader program will also be presented.

“We are excited to share new preclinical data at this year’s AACR conference further strengthening the promise of our differentiated programs,” said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. “Importantly, enrollment and dose escalation are on track in the ongoing Phase 1 trial evaluating FHD-909, a first-in-class oral selective SMARCA2 inhibitor, in SMARCA4 mutated cancers with initial focus in NSCLC. New preclinical data on expansion opportunities for FHD-909 in combination with chemotherapy, pembrolizumab and KRAS inhibitors, in SMARCA4 mutant cancers will be featured in an oral presentation. We look forward to continued progress on our FHD-909 program in collaboration with Lilly.”

Mr. Gottschalk added, “Our Selective CBP degrader and Selective EP300 degrader programs have shown highly selective and robust anti-tumor activities, and two poster presentations will highlight preclinical data supporting their advancement towards the clinic. Our pipeline programs continue to show unmatched selectivity for challenging targets, and we are focused on strong execution across our portfolio.”

Presentation Details


FHD-909

Oral Presentation Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors

Mini Symposium: Experimental and Molecular Therapeutics – Continuum of Innovation: Biological Therapeutic Agents
Session Date/Time: Monday, April 28, 2:30 p.m. – 4:30 p.m. CDT
Presenter: Nathan Brooks, Pharmacology Team Leader, Oncology, Eli Lilly And Company

Poster Presentation Title: A First-in-human Phase 1 Study of LY4050784, an Oral, Potent, and Selective SMARCA2 Inhibitor, in Patients with Advanced Solid Tumors with SMARCA4 Alterations (Trial in Progress)

Session: Phase I Clinical Trials in Progress 1
Poster Number: 51/4
Session Date/Time: Monday, April 28, 2:00 p.m. – 5:00 p.m. CDT
Presenter: Timothy A. Yap, MBBS, PhD, FRCP, Professor of Investigational Cancer Therapeutics, MD Anderson Cancer Center


Selective CBP Degrader

Poster Presentation Title: Establishing rational combination strategies with selective CBP degraders in solid tumor indications

Session: Experimental and Molecular Therapeutics – Degraders and Glues 2
Poster Number: 18 / 3
Session Date/Time: Monday, April 28, 9:00 a.m. – 12:00 p.m. CDT
Presenter: Molly M. Wilson, Scientist, Biology, Foghorn Therapeutics


Selective EP300 Degrader

Poster Title: Anti-cancer activity of potent and selective EP300 degradation in hematological malignancies

Session: Clinical Research – Molecular Genetics and Epigenetics of Tumors
Poster Number: 34 / 17
Session Date/Time: Wednesday, April 30, 9:00 a.m. – 12:00 p.m. CDT
Presenter: Claudia Dominici, Scientist, Biology, Foghorn Therapeutics

The presentation and the posters will be accessible under the Science section of the Company’s website after the conference.

About FHD-909

FHD-909 (LY4050784) is a potent, first-in-class, allosteric and orally available small molecule that selectively inhibits the ATPase activity of SMARCA2 (BRM) over its closely related paralog SMARCA4 (BRG1), two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, tumors with mutations in SMARCA4 rely on SMARCA2 for BAF function. FHD-909 has shown significant anti-tumor activity across multiple SMARCA4 mutant lung tumor models.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s clinical trials, including the ongoing Phase 1 trial evaluating FHD-909, a first-in-class oral selective SMARCA2 inhibitor, in SMARCA4 mutated cancers, product candidates and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.

Contact:

Karin Hellsvik, Foghorn Therapeutics Inc.
[email protected]



Posted on

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control
through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors

• New preclinical data for IO170 add to growing body of evidence supporting the potential of immune-modulatory therapeutic cancer vaccines to treat a wide range of cancers

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, Illinois. One of the posters will share insights, using non-clinical models, related to IO Biotech’s lead investigational candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 trial in advanced melanoma. The second poster contains new preclinical data for the third candidate in the company’s pipeline, IO170, which targets transforming growth factor beta (TGF-beta). Additionally, Mads Hald Andersen, DMSc, PhD, Director of the Center for Cancer Immune Therapy (CCIT) and scientific co-founder of IO Biotech, will be chairing and speaking at an education session on cancer vaccines.

“We are pleased to share new data at AACR that expand our understanding of the underlying mechanism of action of our lead candidate, IO102-IO103, currently being investigated in a pivotal Phase 3 trial,” said Ayako Wakatsuki Pedersen, PhD, Senior Vice President of Translational Research at IO Biotech. “We are also excited to share that we have seen promising activity for an additional candidate being studied in our pipeline, IO170. Together, the data from both of these non-clinical studies further solidify the potential of our proprietary T-win immune-modulatory cancer vaccine platform.”

Dr. Pedersen continued, “We also look forward to the educational session on cancer vaccines, chaired by our scientific founder, that will explore the latest advances in cancer vaccine research and the distinct mechanisms of action of different approaches and their potential to reshape cancer immunotherapy.”

Presentation Details

Title: Immune-modulatory therapeutic cancer vaccines against IDO1 and PD-L1 control tumor growth through target specific changes in the tumor microenvironment
Abstract Number: 2241
Date and Time: Monday, April 28, 2025, 9:00 AM – 12:00 PM CT
Location: Poster Section 38
Poster Board Number: 12
Presenter: Marion Chapellier, PhD

Title: A TGFβ-directed immune-modulatory vaccine induces T cell activation and drives antitumor activity by modulating the tumor microenvironment
Abstract Number: 2257
Date and Time: Monday, April 28, 2025, 9:00 AM – 12:00 PM CT
Location: Poster Section 38
Poster Board Number: 28
Presenter: Justin Joseph, PhD

Education Session: Immune Modulatory Vaccines
This session will explore the latest advancements in cancer vaccine research, spanning from preclinical innovation to clinical translation.
Session: ED59. Cancer Vaccines 101
Date and Time: Saturday, April 26, 2025, 12:30 – 2:00 pm CT
Session format and speakers:

  1. Dr. Smita Nair (30 min, including discussion)
  2. Dr. Kristen Radford (30 min, including discussion)
  3. Dr. Mads Hald Andersen (30 min, including discussion)

About IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead investigational cancer vaccine candidate, Cylembio® (imsapepimut and etimupepimut, adjuvanted) also known as IO102-IO103 in clinical trials, and additional pipeline candidates through preclinical development. Based on positive Phase 1/2 first line metastatic melanoma data, IO102-IO103, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been granted a Breakthrough Therapy Designation for the treatment of advanced melanoma by the US Food and Drug Administration. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.

For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).

Cylembio is a trademark of IO Biotech ApS.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding the timing or outcome of primary analysis of the company’s Phase 3 trial, other current or future clinical trials, their progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

Contact:

Investors

Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
[email protected]

Media

Julie Funesti
Edelman
917-498-1967
[email protected]